These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 572275

  • 1. Functional significance of antibody formation after long-term salmon calcitonin therapy.
    Hosking DJ, Denton LB, Cadge B, Martin TJ.
    Clin Endocrinol (Oxf); 1979 Mar; 10(3):243-52. PubMed ID: 572275
    [Abstract] [Full Text] [Related]

  • 2. Paget's bone disease: response to human calcitonin in patients resistant to salmon calcitonin.
    Rojanasathit S, Rosenberg E, Haddad JG.
    Lancet; 1974 Dec 14; 2(7894):1412-5. PubMed ID: 4140329
    [No Abstract] [Full Text] [Related]

  • 3. Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance.
    Singer FR, Fredericks RS, Minkin C.
    Arthritis Rheum; 1980 Oct 14; 23(10):1148-54. PubMed ID: 7000081
    [Abstract] [Full Text] [Related]

  • 4. Treatment of Paget's disease of bone with porcine calcitonin.
    Eisman JA, Xipell JM, Sloman JG, Jerums G, Martin TJ.
    Med J Aust; 1974 Apr 13; 1(15):564-8. PubMed ID: 4858264
    [No Abstract] [Full Text] [Related]

  • 5. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease.
    Levy F, Muff R, Dotti-Sigrist S, Dambacher MA, Fischer JA.
    J Clin Endocrinol Metab; 1988 Sep 13; 67(3):541-5. PubMed ID: 3410939
    [Abstract] [Full Text] [Related]

  • 6. Calcitonin resistance: clinical and immunologic studies in subjects with Paget's disease of bone treated with porcine and salmon calcitonins.
    Haddad JG, Caldwell JG.
    J Clin Invest; 1972 Dec 13; 51(12):3133-41. PubMed ID: 4674398
    [Abstract] [Full Text] [Related]

  • 7. Clinical significance of antibodies against calcitonin.
    Grauer A, Ziegler R, Raue F.
    Exp Clin Endocrinol Diabetes; 1995 Dec 13; 103(6):345-51. PubMed ID: 8788305
    [Abstract] [Full Text] [Related]

  • 8. Development and significance of antibodies to salmon calcitonin in patients with Paget's disease on long-term treatment.
    Woodhouse NJ, Mohamedally SM, Saed-Nejad F, Martin TJ.
    Br Med J; 1977 Oct 08; 2(6092):927-9. PubMed ID: 410477
    [Abstract] [Full Text] [Related]

  • 9. Paget's disease of the bone: observations after cessation of long-term synthetic salmon calcitonin treatment.
    Avramides A, Flores A, DeRose J, Wallach S.
    J Clin Endocrinol Metab; 1976 Mar 08; 42(3):459-63. PubMed ID: 1254686
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of intranasal human calcitonin in patients with Paget's disease refractory to salmon calcitonin.
    Muff R, Dambacher MA, Perrenoud A, Simon C, Fischer JA.
    Am J Med; 1990 Aug 08; 89(2):181-4. PubMed ID: 2382666
    [Abstract] [Full Text] [Related]

  • 11. Neutralizing antibodies against calcitonin.
    Grauer A, Reinel HH, Ziegler R, Raue F.
    Horm Metab Res; 1993 Sep 08; 25(9):486-8. PubMed ID: 8225203
    [Abstract] [Full Text] [Related]

  • 12. Proceedings: Effect of salmon calcitonin treatment on bone turnover, cardiac output and oxygen transport in patients with Paget's disease.
    Crosbie WA, Woodhouse NJ.
    Clin Sci Mol Med; 1974 Aug 08; 47(2):5P-6P. PubMed ID: 4472253
    [No Abstract] [Full Text] [Related]

  • 13. Paradoxical acute hypercalcemic effect of salmon calcitonin in patients having Paget's disease of bone after treatment with dichloromethylene diphosphonate.
    Delmas PD, Chapuy MC, Meunier PJ.
    Horm Metab Res; 1984 May 08; 16(5):258-61. PubMed ID: 6234216
    [Abstract] [Full Text] [Related]

  • 14. In vitro detection of neutralizing antibodies after treatment of Paget's disease of bone with nasal salmon calcitonin.
    Grauer A, Raue F, Schneider HG, Frank-Raue K, Ziegler R.
    J Bone Miner Res; 1990 Apr 08; 5(4):387-91. PubMed ID: 2343778
    [Abstract] [Full Text] [Related]

  • 15. Formation of antibodies to synthetic human calcitonin during treatment of Paget's disease.
    Dietrich FM, Fischer JA, Bijvoet OL.
    Acta Endocrinol (Copenh); 1979 Nov 08; 92(3):468-76. PubMed ID: 517048
    [Abstract] [Full Text] [Related]

  • 16. [New method of measuring total and regional bone fixation of calcium in patients with Paget's disease treated with salmon calcitonin].
    Bergmann P, Schoutens A, Corvilain J.
    Strahlentherapie Sonderb; 1975 Nov 08; 74():301-8. PubMed ID: 1239103
    [No Abstract] [Full Text] [Related]

  • 17. Long-term treatment of Paget's disease of bone with salmon calcitonin.
    Sturtridge WC, Harrison JE, Wilson DR.
    Can Med Assoc J; 1977 Nov 05; 117(9):1031-4. PubMed ID: 562231
    [Abstract] [Full Text] [Related]

  • 18. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis.
    Muff R, Dambacher MA, Fischer JA.
    Osteoporos Int; 1991 Feb 05; 1(2):72-5. PubMed ID: 1790395
    [Abstract] [Full Text] [Related]

  • 19. An evaluation of antibodies and clinical resistance to salmon calcitonin.
    Singer FR, Aldred JP, Neer RM, Krane SM, Potts JT, Bloch KJ.
    J Clin Invest; 1972 Sep 05; 51(9):2331-8. PubMed ID: 4674133
    [Abstract] [Full Text] [Related]

  • 20. Bone turnover in Paget's disease: biochemical and kinetic measurements during salmon calcitonin therapy.
    Hosking DJ, Vennart W, Huddlestone LB.
    Calcif Tissue Int; 1981 Sep 05; 33(5):471-6. PubMed ID: 6797699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.